- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01276899
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
This is a multicenter translational study to understand therapeutic resistance in patients undergoing standard chemotherapy for triple negative breast cancer.
In the neoadjuvant setting, biopsy tissue samples from primary tumor will be collected and banked before the start of chemotherapy and after the completion of the treatment (post-chemotherapy and at the time of surgery). In the metastatic setting, tissue samples from metastatic lesions will be collected and banked before the start of chemotherapy and at the time of tumor progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment. All samples will be stored in the Biological Resource Repository.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mechanisms of resistance have been studied for many years in various experimental models. However, many drugs that are highly effective in experimental models at overcoming resistance have been either ineffective or marginally active in preliminary clinical studies. Thus after decades of study, most reviews of anti-cancer drug resistance still focus largely on experimental models, which may not reflect resistance in humans. However, recent studies have demonstrated that clinical resistance occurs in primary and metastatic tumors that may have undergone significant molecular evolution due to treatment effects and the selection of clones as recently shown in breast cancer.
Triple negative breast cancer is a subtype that carries a poor prognosis and a high incidence of early metastatic recurrence. Furthermore, no target therapy is efficacious up to now in this subtype. Thus, identification of mechanisms of resistance to available therapies and prediction of tumoral response to various treatments could help in the management of patients affected by this particularly aggressive type of breast cancer.
The goals of this study are two-fold. First, to build a biobank of blood and tissue specimens, prior to starting chemotherapy and at a determined time-point (surgery or progression of disease), from patients undergoing the chemotherapeutic treatments in the neoadjuvant and metastatic settings. Second, to use cutting-edge molecular techniques available in several Quebec research centers, to carefully compare these pre and post treatment samples to identify "molecular factors of resistance". The discovery of these factors will help oncologists in triaging patients to receive the most beneficial therapy by recognizing when not to give particular treatment and will be essential for reducing the potential for harmful side effects and for avoiding the extremely high cost of modern treatments when they can be predicted to be ineffective.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada
- Hopital du St-Sacrement
-
-
Quebec
-
Montreal, Quebec, Canada
- Jewish General Hospital
-
Montreal, Quebec, Canada
- Centre Hospitalier de l'Université de Montréal -- Hotel-Dieu
-
Montreal, Quebec, Canada
- Centre Hospitalier de l'Université de Montréal- Notre-Dame
-
Montreal, Quebec, Canada
- Hôpital Royal Victoria
-
Montreal, Quebec, Canada
- Hopital Sacre-Coeur
-
Montreal, Quebec, Canada
- St-Mary's Hospital Center
-
-
-
-
Illinois
-
Chicago, Illinois, United States
- John H. Stroger, Jr. Hospital of Cook County
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Neoadjuvant setting
- Histologically confirmed diagnosis of adenocarcinoma of the breast
- Patient candidate for neoadjuvant chemotherapy (taxane-based)
- Triple negative (ERnegative, PRnegative and Her2negative as defined by local standards)
- Normal coagulation profile; including INR/ PTT ≤ 1.5 x ULN.
- ECOG 0,1 or 2
- Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
- Able to adhere to the study visit schedule and other protocol requirements.
Metastatic setting
- Patients with histologically confirmed primary adenocarcinoma of the breast
- Metastatic (stage IV) disease at initial diagnosis or following previous diagnosis of primary breast cancer
- At least one metastatic site accessible for biopsy.
- ER-negative, PgR negative and HER2 negative as per local standards
- Scheduled to receive chemotherapy for triple negative metastatic breast cancer.
- Measurable disease (at least one unidimensionally measurable lesion)
- Normal coagulation profile; including INR/ PTT ≤ 1.5 x ULN.
- ECOG 0,1 or 2
- Life expectancy of 12 or more weeks.
- Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
- Able to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
Neoadjuvant setting
- Positive for ER, PR or Her2 as defined by local standards
- Clinical or radiological evidence of metastatic disease
- Inadequate or unusable tissue as the only tissue available for biopsy
- Other non-malignant systemic disease to preclude treatment with chemotherapy regimen or prevent follow-up
- Diagnosis of inflammatory breast cancer
- Known infection with HIV or hepatitis
Metastatic setting
- Patients with ER+, PR+ or HER2+ tumors demonstrated by local standards
- Inadequate or unusable tissue as the only tissue available for biopsy
- Other non-malignant systemic disease to preclude treatment with standard chemotherapy regimen or prevent follow-up
- Abnormal coagulation profile
- The planned concurrent administration of therapies (e.g. palliative radiotherapy) that target metastatic sites accessible for biopsy
- Known infection with HIV or hepatitis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Neoadjuvant setting
|
No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples. A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank. |
Metastatic setting
|
No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples. Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Biomarkers changes in patients that have been exposed to chemotherapy
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Create a unique bank of biospecimens from patients with triple negative breast tumors comprising tumor material and plasma collected in a specific and well defined clinical context.
Time Frame: 2 years
|
2 years
|
Study mechanisms of resistance to chemotherapy by profiling for the first time resistant tumors in both the metastatic and advanced primary tumor settings.
Time Frame: 3 years
|
3 years
|
Identify biomarkers that will be used as predictors of therapeutic resistance in the tissue and blood of patients with triple negative breast tumors
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Basik, MD, Segal Cancer Centre, Jewish General Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Breast Cancer
- Biomarkers
- Resistance
- Neoadjuvant chemotherapy
- Metastases
- Triple negative breast cancer
- Taxanes
- Biobanking
- ERnegative, PRnegative and Her2negative
- Breast cancer with unresectable metastases to the liver
- Breast cancer with unresectable metastases to the skin
- Breast cancer with unresectable metastases to the lymph node
Additional Relevant MeSH Terms
Other Study ID Numbers
- Q-CROC-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on Needle core biopsies
-
Sunnybrook Health Sciences CentreAFP Innovation FundRecruitingBreast Cancer | Breast Neoplasms | Metastatic Breast Cancer | Cancer, BreastCanada
-
Jewish General HospitalExactis Innovation; Fonds de la Recherche en Santé du Québec; Terry Fox Research...CompletedColorectal CancerCanada, Belgium
-
Philips HealthcareWithdrawnProstate CancerUnited States
-
Shandong Cancer Hospital and InstituteUnknown
-
Duke UniversityWithdrawn
-
Udo SechtemTerminated
-
Ourotech, Inc.Barts & The London NHS TrustRecruitingTriple Negative Breast Cancer | Triple Negative Breast NeoplasmsUnited Kingdom
-
Rna Diagnostics Inc.RecruitingBreast Neoplasm FemaleGermany, United States, Canada, France, Italy, Spain, Poland
-
Kessler FoundationNew Jersey Commission on Spinal Cord ResearchUnknownSpinal Cord InjuryUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasm of Pancreas | Solid Pancreatic Mass LesionsUnited States